Severe, persistent pain in the upper abdomen — often boring through to the back — with nausea and vomiting that will not stop. That is the pancreatitis pattern.
Stop and seek medical assessment. Persistent vomiting also dehydrates and strains the kidneys — sip fluids.
Unrelenting abdominal pain, repeated vomiting, or signs of dehydration → urgent care or ER. And tell any anaesthetist before surgery: these drugs slow stomach emptying and raise the risk of aspiration under anaesthesia.
Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.
A single molecule agonising two incretin receptors. Tirzepatide is built on a GIP-analog backbone with balanced GLP-1 receptor activity, producing insulinotropic effects through both pathways. GIP receptor engagement in adipose tissue and the CNS appears to contribute effects distinct from GLP-1 alone, though the relative contribution of each arm remains an active research question.
The SURPASS programme in type 2 diabetes and SURMOUNT programme in obesity demonstrated glycaemic and weight outcomes that generally exceeded GLP-1 monotherapy comparators in head-to-head and cross-trial comparison. Additional approval followed for obstructive sleep apnoea in obesity.
FDA-approved for type 2 diabetes and chronic weight management, with an additional indication in obstructive sleep apnoea. Prescription-only.
Boxed warning for rodent thyroid C-cell tumours; same MTC/MEN2 contraindication as GLP-1 agents. Gastrointestinal adverse effects are dose-limiting for many patients. Physician supervision required.
Started at 2.5 mg once weekly SC (a tolerance dose, not therapeutic), titrated to maintenance of 5, 10 or 15 mg once weekly, per the SURPASS and SURMOUNT programmes and FDA label.
Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.
Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.